ANDA 202101, held by Alembic. Aripiprazole.
As of Nov 16, 2026, ANDA 202101 (Aripiprazole), held by Alembic, was first approved by FDA on Apr 28, 2015, with 6 approved supplements and 0 published complete response letters.
Aripiprazole is indicated for the treatment of:
| Date | Submission | Status | Documents |
|---|---|---|---|
| Apr 28, 2015 | Original application | Approved |
| Aripiprazole2MG · tablet;oral | Aripiprazole | Rx |
| Aripiprazole5MG · tablet;oral | Aripiprazole | Rx |
| Aripiprazole10MG · tablet;oral | Aripiprazole | Rx |
| Aripiprazole15MG · tablet;oral | Aripiprazole | Rx |
| Aripiprazole20MG · tablet;oral | Aripiprazole | Rx |
| Aripiprazole30MG · tablet;oral | Aripiprazole | Rx |
| May 28, 2024 | Supplement 5Labeling · Standard review | Approved | None posted |
| May 28, 2024 | Supplement 12Labeling · Standard review | Approved | None posted |
| May 28, 2024 | Supplement 13Labeling · Standard review | Approved | None posted |
| May 28, 2024 | Supplement 20Labeling · Standard review | Approved | None posted |
| Oct 27, 2016 | Supplement 1Labeling · Standard review | Approved | None posted |
| Oct 27, 2016 | Supplement 4Labeling · Standard review | Approved | None posted |
| Apr 28, 2015 | Original application | Approved |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters